Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O0JH
|
|||
| Former ID |
DIB010035
|
|||
| Drug Name |
F-12509A
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Terminated | [1] | |
| Company |
Sankyo Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H28O4
|
|||
| Canonical SMILES |
CC1(CCCC2(C1CCC(=C)C2CC3=C(C(=O)C=C(C3=O)O)O)C)C
|
|||
| InChI |
1S/C21H28O4/c1-12-6-7-17-20(2,3)8-5-9-21(17,4)14(12)10-13-18(24)15(22)11-16(23)19(13)25/h11,14,17,22,25H,1,5-10H2,2-4H3/t14-,17-,21+/m0/s1
|
|||
| InChIKey |
KFAYECQGXSDHKU-XXHMAFKTSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine kinase 1 (SPHK1) | Target Info | Inhibitor | [1] |
| BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
| KEGG Pathway | Sphingolipid metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| VEGF signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Tuberculosis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| Panther Pathway | Angiogenesis | |||
| VEGF signaling pathway | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| Beta3 integrin cell surface interactions | ||||
| S1P1 pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| PDGFR-beta signaling pathway | ||||
| Reactome | Sphingolipid de novo biosynthesis | |||
| VEGFR2 mediated cell proliferation | ||||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Protein folding | ||||
| Sphingolipid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo). 2000 May;53(5):459-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.